Bank Julius Baer & Co. Ltd Zurich Buys New Stake in Axon Enterprise, Inc (NASDAQ:AXON)

Bank Julius Baer & Co. Ltd Zurich acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,497 shares of the biotechnology company's stock, valued at approximately $3,509,000.

A number of other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC increased its stake in Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock worth $1,095,542,000 after buying an additional 65,097 shares in the last quarter. Capital World Investors increased its stake in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after buying an additional 841,772 shares in the last quarter. Alliancebernstein L.P. increased its stake in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after buying an additional 812,337 shares in the last quarter. Norges Bank purchased a new stake in Axon Enterprise in the 4th quarter worth $482,081,000. Finally, GAMMA Investing LLC increased its stake in Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after buying an additional 763,431 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insider Activity at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $738.84, for a total value of $960,492.00. Following the completion of the sale, the director owned 4,829 shares of the company's stock, valued at $3,567,858.36. This represents a 21.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Joshua Isner sold 905 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total transaction of $702,632.95. Following the completion of the sale, the president directly owned 268,735 shares of the company's stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,642 shares of company stock worth $25,090,528 in the last 90 days. 4.40% of the stock is owned by insiders.

Axon Enterprise Stock Performance

NASDAQ AXON traded up $25.75 on Friday, reaching $735.01. 654,601 shares of the company's stock traded hands, compared to its average volume of 627,317. The stock has a 50 day moving average price of $763.82 and a 200-day moving average price of $650.42. The firm has a market cap of $57.22 billion, a price-to-earnings ratio of 177.54, a P/E/G ratio of 79.06 and a beta of 1.29. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $830.21. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The company's revenue for the quarter was up 31.3% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AXON. UBS Group began coverage on Axon Enterprise in a research note on Wednesday, July 16th. They issued a "neutral" rating and a $820.00 price target for the company. JMP Securities raised their price objective on Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a research report on Tuesday. Bank of America raised their price objective on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, The Goldman Sachs Group raised their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $772.08.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.